Drugs / PREXIGEBERSEN
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01159028 | Jun 2010 → Mar 2017 | Philadelphia-positive myelogenous leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Bio-Path Holdings, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02923986 | Sep 2017 → May 2020 | Philadelphia-positive myelogenous leukemia, acute myeloid leukemia, myelodysplastic syndrome | Bio-Path Holdings, Inc. | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02781883 | May 2016 → Dec 2027 expected | acute myeloid leukemia | Bio-Path Holdings, Inc. | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PREXIGEBERSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989978 ↗ |
| Known as | BP-100-1.01/L-Grb2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989978 ↗ |
| Known as | BP1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781883 ↗ |
| Known as | L-grb-2 antisense | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989978 ↗ |
| Known as | L-Grb2 AS | “The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide...” NCT01159028 ↗ |
| Action | Inhibit | “inhibit the cells from making Grb-2” NCT01159028 ↗ |
| Modality | Antisense oligonucleotide | “antisense oligodeoxynucleotide” NCT01159028 ↗ |
| Route | Intravenous | “administered by IV on twice weekly for 28 days” NCT01159028 ↗ |
| Target | GRB2 | “inhibit the cells from making Grb-2” NCT01159028 ↗ |